VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
"I am pleased that Dr. Day and Dr. Garvey can share the results of the phase 3 obesity studies and phase 2 obesity studies with our colleagues in the medical and pharmaceutical community," stated Leland Wilson, president and chief executive officer of VIVUS. "We are actively pursuing a comprehensive presentation and publication strategy, and are excited by the opportunity to communicate these data at Obesity Society's annual meeting. We look forward to additional presentations in the future with the ultimate goal of publication in a top-tier medical journal."
Where is childhood obesity growing fastest in England?